Nav: Home

FEFU scientists teamed up with colleagues to develop ointment for skin cancer prevention

July 02, 2019

Scientists from Far Eastern Federal University (FEFU), V.I. Vernadsky Crimean Federal University, Dmitry Mendeleev University of Chemical Technology, and Far Eastern Branch of the Russian Academy of Sciences (FEB RAS), assumed the risks of primary skin cancer and its recurrences can be significantly reduced by applying the ointment with antisense oligonucleotides which are short DNA, RNA fragments used in oncology to suppress the synthesis of tumor proteins. A related review was published in Molecules.

The role of antisense oligonucleotides is to support the functions of proteins responsible for apoptosis in the human body. This natural mechanism allows cells to carry out programmed death. As a result of skin exposure to primary damaging factors, such as ultraviolet (natural sunlight, tanning machines UV), these proteins may be restrained to function in the transformed cells, thus the regulation of apoptosis is violating, in some cases it becomes impossible. Due to this, the cells begin to divide uncontrollably and mutate resulting in the tumor occurrence.

The most reliable way to get rid of skin cancer is to cut it out surgically. However, at different stages of tumor progression, especially concerning the most aggressive and lethal types of skin cancer - melanoma and Merkel carcinoma - it's difficult to recognize the tumor boundaries and depth. Thus, for a surgeon, it's not clear how much tissues around a tumor area should be removed. The fact is that these tissues may hide isolated tumor cells, which may provoke the relapse of cancer in the future. To cope with that, we consider special ointments as promising treatment, which we suggest as an additional measure to surgical excision. Ointments will help patients to get free of some aesthetic defects that inevitably follow the surgery. In some cases, at the initial stages of the malignancy, ointment-based treatment, perhaps, will allow one to completely avoid the operation.' Vadim Kumeiko said, Deputy Director for Development, Head of Laboratory of Biomedical Cell Technologies, FEFU School of Biomedicine.

The researchers are focused on the development of an ointment containing antisense oligonucleotides for BCL-2 and survivin proteins. It will be designed to fight over melanoma, the most deadly type of skin cancer. The components of the ointment will penetrate the stratum corneum, and reach the melanocytes and progenitor cells, the mutation of which can lead to the development of a deadly tumor.

One of the main challenges in the development of such an ointment remains the speed of delivery of antisense oligonucleotides into cancerous tissues. These compounds are unstable and can lose their effectiveness even before they reach damaged skin cells. For the same reason, the strategy of direct topical application of the ointment at the area of the damaged cells seems to be more effective comparing to other delivering routes, for example, intravenous.

Skin cancer remains the most common type of malignancy. It accounts for one of the three cases of cancer diagnosed. Ultraviolet radiation of natural and artificial origin is one of the main factors affecting the mutation of human skin cells into tumor cells. As a rule, cancer occurs on the skin areas which are most often exposed to the natural sunlight or tanning machines UV. Men and women of different ages and skin color are vulnerable to skin cancer. In the high-risk group are the elderly, people with white or light-colored skin, with blue eyes, as well as redheads.
-end-
The work was supported by funding under the Development Program of V.I. Vernadsky Crimean Federal University for 2015-2024.

Far Eastern Federal University

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...